4,898 reports of this reaction
4.5% of all GLATIRAMER ACETATE reports
#2 most reported adverse reaction
INJECTION SITE PAIN is the #2 most commonly reported adverse reaction for GLATIRAMER ACETATE, manufactured by Teva Neuroscience, Inc.. There are 4,898 FDA adverse event reports linking GLATIRAMER ACETATE to INJECTION SITE PAIN. This represents approximately 4.5% of all 108,384 adverse event reports for this drug.
Patients taking GLATIRAMER ACETATE who experience injection site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE PAIN is moderately reported among GLATIRAMER ACETATE users, representing a notable but not dominant share of adverse events.
In addition to injection site pain, the following adverse reactions have been reported for GLATIRAMER ACETATE:
The following drugs have also been linked to injection site pain in FDA adverse event reports:
INJECTION SITE PAIN has been reported as an adverse event in 4,898 FDA reports for GLATIRAMER ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE PAIN accounts for approximately 4.5% of all adverse event reports for GLATIRAMER ACETATE, making it one of the most commonly reported side effect.
If you experience injection site pain while taking GLATIRAMER ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.